Jacob D Soumerai and Andrew D Zelenetz on the BOVen regimen for previously untreated patients with chronic lymphocytic leukaemia

Dr Jacob D Soumerai and Prof Andrew D Zelenetz discuss their phase 2 trial of the BOVen regimen and MRD-driven treatment discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00307-0/fulltext  Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv The Lancet Haematology in conversation with...  is part of the Lancet Group podcast offering.  Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin Podcast editing: Matteo Simonetti Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering.  Find the best science for better lives at www.thelancet.com Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv